Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov 30;14(11):7472-7477.
doi: 10.21037/tcr-2025-1837. Epub 2025 Nov 26.

Translating NSABP B-51 findings into practice: rethinking regional nodal irradiation in breast cancer

Kefah Mokbel  1 , Muharrem Oner  1
Affiliations
Editorial

Translating NSABP B-51 findings into practice: rethinking regional nodal irradiation in breast cancer

Kefah Mokbel et al. Transl Cancer Res. .
No abstract available

Keywords: Breast cancer; HER2-positive breast cancer; neoadjuvant chemotherapy (NAC); regional nodal irradiation (RNI); triple-negative breast cancer (TNBC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-1837/coif). The authors have no conflicts of interest to declare.

Comment on

  • Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
    Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li XA, McCormick B, Smith B, Tendulkar RD, Kavadi VS, Matsumoto K, Seaward SA, Irvin WJ Jr, Lin JY, Mutter RW, Muanza TM, Stromberg J, Jagsi R, Weiss AC, Curran WJ Jr, Wolmark N. Mamounas EP, et al. N Engl J Med. 2025 Jun 5;392(21):2113-2124. doi: 10.1056/NEJMoa2414859. N Engl J Med. 2025. PMID: 40466065 Free PMC article. Clinical Trial.

References

    1. Mamounas EP, Bandos H, White JR, et al. Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy. N Engl J Med 2025;392:2113-24. 10.1056/NEJMoa2414859 - DOI - PMC - PubMed
    1. Ito M, Amari M, Sato A, et al. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. Breast. 2024;73:103604. 10.1016/j.breast.2023.103604 - DOI - PMC - PubMed
    1. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017;376:2147-59. 10.1056/NEJMoa1612645 - DOI - PubMed
    1. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019;380:617-28. 10.1056/NEJMoa1814017 - DOI - PubMed
    1. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol 2024;42:987-93. 10.1200/JCO.23.01994 - DOI - PMC - PubMed